Rubius Therapeutics Inc. (RUBY)
$0.06
$0.04
(171.43%)
As on 29-Dec-2023 15:49EDT
Market cap
$5 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-180 Mln
-
ROE
-1.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.1
-
Debt to Equity
0.1
-
Book Value
$0.2
-
EPS
$-2.6
-
Face value
--
-
Shares outstanding
90,483,000
7 Years Aggregate
CFO
$-623.14 Mln
EBITDA
$-776.06 Mln
Net Profit
$-886.25 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Rubius Therapeutics (RUBY)
| -67.4 | -- | -- | -76.2 | -80.5 | -67.7 | -- |
|
BSE Sensex*
| -10.9 | -4.9 | -8.9 | -7.6 | 6.9 | 8.3 | 11.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|
|
Rubius Therapeutics (RUBY)
| -98.2 | 27.5 | -20.1 | -40.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Rubius Therapeutics (RUBY)
|
0.1 | 5.2 | 0.0 | -230.9 | -- | -238.1 | -- | 0.3 |
| 75.0 | 10,557.2 | 622.0 | -300.9 | -25.7 | -61.1 | -- | 17.3 | |
| 76.9 | 10,446.2 | 105.8 | -829.6 | -715.0 | -- | -- | 60.3 | |
| 50.2 | 12,605.5 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.6 | 6.4 | |
| 119.0 | 15,772.8 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 | |
| 68.3 | 8,103.6 | 1,508.5 | 348.8 | 57.0 | 96.4 | 24 | 36.9 | |
| 299.5 | 8,827.7 | 417.3 | 225.0 | 42.8 | 18.6 | 40 | 6.9 | |
| 517.3 | 11,925.8 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 22.0 | |
| 432.8 | 12,360.6 | 2,678.3 | 460.4 | 21.1 | 103.2 | 27.3 | 20.7 | |
| 343.6 | 9,578.0 | 0.0 | -326.5 | -- | -37.2 | -- | 6.8 |
Shareholding Pattern
View DetailsAbout Rubius Therapeutics (RUBY)
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius... Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts. Read more
-
CEO & Pres
Ms. Dannielle Appelhans
-
CEO & Pres
Ms. Dannielle Appelhans
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Rubius Therapeutics (RUBY)
What is the current share price of Rubius Therapeutics Inc (RUBY) Today?
The share price of Rubius Therapeutics Inc (RUBY) is $0.06 (NASDAQ) as of 29-Dec-2023 15:49 EDT. Rubius Therapeutics Inc (RUBY) has given a return of -80.48% in the last 3 years.
What is the current PB & PE ratio of Rubius Therapeutics Inc (RUBY)?
Since, TTM earnings of Rubius Therapeutics Inc (RUBY) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.07
|
1.04
|
|
2021
|
-4.61
|
4.87
|
|
2020
|
-3.79
|
4.34
|
|
2019
|
-4.72
|
2.76
|
|
2018
|
-13.84
|
3.14
|
What is the 52 Week High and Low of Rubius Therapeutics Inc (RUBY)?
The 52-week high and low of Rubius Therapeutics Inc (RUBY) are Rs -- and Rs -- as of 24-May-2026.
What is the market cap of Rubius Therapeutics Inc (RUBY)?
Rubius Therapeutics Inc (RUBY) has a market capitalisation of $ 5 Mln as on 29-Dec-2023. As per SEBI classification, it is a company.
Should I invest in Rubius Therapeutics Inc (RUBY)?
Before investing in Rubius Therapeutics Inc (RUBY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.